BRII - B(02137),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02137 BRII - B

Market Closed 11-15 16:08:33

1.070

-0.010

-0.93%

High1.110	Low1.060	Vol586.50K
Open1.090	D1 Closing1.080	Amplitude4.63%
Mkt Cap781.24M	Tradable Cap781.24M	Total Shares730.14M
T/O638.37K	T/O Rate0.08%	Tradable Shares730.14M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02137","market":"HK","secType":"STK","nameCN":"BRII - B","latestPrice":1.07,"timestamp":1731658113016,"preClose":1.08,"halted":0,"volume":586500,"delay":0,"floatShares":730135230,"shares":730135230,"eps":-0.258217610258167,"marketStatus":"Market Closed","change":-0.01,"latestTime":"11-15 16:08:33","open":1.09,"high":1.11,"low":1.06,"amount":638365,"amplitude":0.046296,"askPrice":1.09,"askSize":30000,"bidPrice":1.07,"bidSize":18000,"shortable":0,"etf":0,"ttmEps":-0.3914602027809785,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1731893400000},"marketStatusCode":7,"adr":0,"listingDate":1626105600000,"exchange":"SEHK","adjPreClose":1.08,"openAndCloseTimeList":[[1731634200000,1731643200000],[1731646800000,1731657600000]],"volumeRatio":0.49872448974502814,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02137","defaultTab":"news","newsList":[{"id":"2460703641","title":"Brii Biosciences Records Wider Loss in H1 on Nil Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2460703641","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460703641?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:58","pubTimestamp":1724072313,"startTime":"0","endTime":"0","summary":"Brii Biosciences  recorded a loss attributable to owners of 280.5 million yuan for the six months ended June 30, wider than 189.9 million yuan logged for the same period last year, a Monday filing with the Hong Kong Exchange said.The company saw a loss per share of 0.38 yuan for the reporting period as compared to the 0.26 yuan per share from the year-ago period.The company reported a nil revenue for the first half of this year due to the discontinuation of COVID-19 programs. It posted 617,000 yuan revenue in the year-ago period.The company's shares were over 3% up on Monday's close.Price : $0.98, Change: $+0.030, Percent Change: +3.16%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02137"],"gpt_icon":0},{"id":"2460270036","title":"Brii Biosciences Records Wider Loss in H1 on Nil Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2460270036","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460270036?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:58","pubTimestamp":1724072313,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["HKD","BNTX","BK1587","BK4585","02137","BK1574","BK4588","BK4526","BK4023","BK1161"],"gpt_icon":0},{"id":"2460038971","title":"BRIEF-Brii Biosciences Posts HY Loss RMB283.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2460038971","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460038971?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:07","pubTimestamp":1724069255,"startTime":"0","endTime":"0","summary":"Aug 19 (Reuters) - Brii Biosciences Ltd   :   * HY LOSS RMB283.2 MILLIONFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1587","BK1574","02137"],"gpt_icon":0},{"id":"2460087193","title":"Brii Biosciences - Hy Loss RMB283.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2460087193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460087193?lang=en_us&edition=fundamental","pubTime":"2024-08-19 19:32","pubTimestamp":1724067137,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240819:nFWN3K60UZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1161","02137","BK1574"],"gpt_icon":0},{"id":"2455979124","title":"Brii Biosciences Says Unaffected by VBI Vaccines' Restructuring Under Creditors Arrangement Act, Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2455979124","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2455979124?lang=en_us&edition=fundamental","pubTime":"2024-07-31 15:05","pubTimestamp":1722409535,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK1574","BK4585","BK4526","BK1587","VBIV","BK4139","BK4588","BK1161","HKD","02137","BK4023"],"gpt_icon":0},{"id":"2455794429","title":"Brii Biosciences Says Unaffected by VBI Vaccines' Restructuring Under Creditors Arrangement Act, Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2455794429","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2455794429?lang=en_us&edition=fundamental","pubTime":"2024-07-31 15:05","pubTimestamp":1722409535,"startTime":"0","endTime":"0","summary":"Brii Biosciences  does not expect any effect on its operations or finances due to the initiation of restructuring procedures under the \"Companies' Creditors Arrangement Act\" by one of its partners, VBI Vaccines, a Wednesday filing with the Hong Kong Exchange said.The company also disclosed in the filing that it has already reserved a worldwide exclusive license to BRII-179 and the exclusive rights of PreHevbri in Asia Pacific regions excluding Japan, which it obtained from VBI on July 6, 2023, leaving the company unaffected by the indebtedness of VBI.The company's shares were up 3% in recent trade.Price : $1.02, Change: $+0.03, Percent Change: +3.03%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4023","HKD","02137","BK4139","VBIV","BK4585","BK4526","BK1574","BK4588","BK1161","BK1587"],"gpt_icon":0},{"id":"2455912708","title":"BRIEF-Brii Biosciences Says On July 30, VBI Vaccines Initiated Restructuring Proceedings","url":"https://stock-news.laohu8.com/highlight/detail?id=2455912708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2455912708?lang=en_us&edition=fundamental","pubTime":"2024-07-31 08:59","pubTimestamp":1722387576,"startTime":"0","endTime":"0","summary":"July 31 (Reuters) - Brii Biosciences Ltd   :   * ON JULY 30, VBI VACCINES INITIATED RESTRUCTURING PROCEEDINGS   * DOES NOT EXPECT MATERIAL IMPACTS ON ITS BUSINESS OPERATION AND FINANCIAL PERFORMANCE DUE TO VBI'S INSOLVENCY Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02137","BK1574","BK1587"],"gpt_icon":0},{"id":"2455891148","title":"Brii Biosciences Ltd -  on July 30, VBI Vaccines Initiated Restructuring Proceedings","url":"https://stock-news.laohu8.com/highlight/detail?id=2455891148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2455891148?lang=en_us&edition=fundamental","pubTime":"2024-07-31 08:01","pubTimestamp":1722384076,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240731:nFWN3JM24U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1161","VBIV","BK1574","BK4139","02137"],"gpt_icon":0},{"id":"2455114539","title":"Brii Biosciences -  Does Not Expect Material Impacts on Its Business Operation and Financial Performance Due to VBI's Insolvency","url":"https://stock-news.laohu8.com/highlight/detail?id=2455114539","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2455114539?lang=en_us&edition=fundamental","pubTime":"2024-07-31 08:01","pubTimestamp":1722384076,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240731:nFWN3JM24U:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1587","02137","BK1574"],"gpt_icon":0},{"id":"2452174588","title":"Institutions profited after Brii Biosciences Limited's (HKG:2137) market cap rose HK$109m last week but individual investors profited the most","url":"https://stock-news.laohu8.com/highlight/detail?id=2452174588","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452174588?lang=en_us&edition=fundamental","pubTime":"2024-07-18 08:36","pubTimestamp":1721262985,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over Brii Biosciences by individual investors implies that the general public has more...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2137/brii-biosciences-shares/news/institutions-profited-after-brii-biosciences-limiteds-hkg213","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1574","BK1587","02137"],"gpt_icon":0},{"id":"2442843850","title":"Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2442843850","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2442843850?lang=en_us&edition=fundamental","pubTime":"2024-06-10 19:20","pubTimestamp":1718018421,"startTime":"0","endTime":"0","summary":"Brii Biosciences  presented new data from two phase 2 studies of BRII-179 for chronic hepatitis B virus infection at the European Association for the Study of the Liver Congress 2024, a June 7 filing on the Hong Kong bourse said. The data presented showed that BRII-179, in combination with BRII-835, demonstrated antiviral effects in participants with chronic HBV infection. Meanwhile, administering BRII-179 on top of pegylated interferon-alpha improved the overall HBsAg loss rate in 114 virally-suppressed subjects with chronic HBV infection.Price : $1.26, Change: $-0.01, Percent Change: -0.79%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HKD","BK1587","BK4585","02137","BK1574","BK4588","BK4526","BK4023","BK1161"],"gpt_icon":0},{"id":"2442843804","title":"Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2442843804","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2442843804?lang=en_us&edition=fundamental","pubTime":"2024-06-10 19:20","pubTimestamp":1718018421,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["HKD","BK1587","BK4585","02137","BK1574","BK4588","BK4526","BK4023","BK1161"],"gpt_icon":0},{"id":"2441599260","title":"Brii Bio Presents New Data From Its Ongoing Phase 2 Chronic Hepatitis B Trials at Easl™ Congress 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2441599260","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2441599260?lang=en_us&edition=fundamental","pubTime":"2024-06-07 19:00","pubTimestamp":1717758004,"startTime":"0","endTime":"0","summary":"Brii Bio Presents New Data From Its Ongoing Phase 2 Chronic Hepatitis B Trials at Easl™ Congress 2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240607:nTUACGDRHQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1574","BK1161","02137"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.briibio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.019},{"period":"3month","weight":0.1263},{"period":"6month","weight":-0.2015},{"period":"1year","weight":-0.5916},{"period":"ytd","weight":-0.5307}],"compareEarnings":[{"period":"1week","weight":-0.0628},{"period":"1month","weight":-0.0424},{"period":"3month","weight":0.1145},{"period":"6month","weight":-0.0065},{"period":"1year","weight":0.0894},{"period":"ytd","weight":0.1395}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.139084},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.166803},{"month":3,"riseRate":0,"avgChangeRate":-0.321072},{"month":4,"riseRate":0.333333,"avgChangeRate":0.044149},{"month":5,"riseRate":0,"avgChangeRate":-0.067206},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.097476},{"month":7,"riseRate":1,"avgChangeRate":0.066427},{"month":8,"riseRate":0.25,"avgChangeRate":0.023974},{"month":9,"riseRate":0.5,"avgChangeRate":-0.020754},{"month":10,"riseRate":0.25,"avgChangeRate":-0.137315},{"month":11,"riseRate":1,"avgChangeRate":0.393141},{"month":12,"riseRate":0,"avgChangeRate":-0.197537}],"exchange":"SEHK","name":"BRII - B","nameEN":"BRII - B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BRII - B(02137),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BRII - B(02137) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BRII - B,02137,BRII - B股票,BRII - B股票老虎,BRII - B股票老虎国际,BRII - B行情,BRII - B股票行情,BRII - B股价,BRII - B股市,BRII - B股票价格,BRII - B股票交易,BRII - B股票购买,BRII - B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BRII - B(02137),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BRII - B(02137) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}